Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

blinatumomab MeSH Supplementary Concept Data 2026


MeSH Supplementary
blinatumomab
Unique ID
C510808
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C510808
Entry Term(s)
Blincyto
MEDI-538
MT-103 antibody
antibody MT-103
Pharm Action
Antineoplastic Agents
Registry Numbers
4FR53SIF3A
0
Heading Mapped to
*Antibodies, Bispecific
Frequency
386
Note
a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma
Source
Curr Opin Mol Ther 2006 Feb;8(1):62-8
Date Introduced
2006/06/08
Last Updated
2019/10/31
blinatumomab Preferred
Blincyto Narrower
MT-103 antibody Narrower
MEDI-538 Narrower
page delivered in 0.008s